WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis

American Journal of Pathology

Volumn 154, Issue 1, 1999, Pages 181-192

  Yang, Youxin ^a   Jeanpierre, Cécile ^a   Dressler, Gregory R ^b   Lacoste, Mireille ^a   Niaudet, Patrick ^a   Gubler, Marie Claire ^a,c  

^a INSERM   (France)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN;

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DENYS DRASH SYNDROME; DNA BINDING; DOWN REGULATION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MESANGIUM CELL; PATHOPHYSIOLOGY; PODOCYTE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSEUDOHERMAPHRODITISM; TUMOR SUPPRESSOR GENE;

EID: 0032921040     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65264-9     Document Type: Article

References (57)

1. Denys P, Malvaux P, van den Berghe H, Tanghe W, Proesmans W: Association d'un syndrome anatomo-pathologique de pseudo-hermaphrodisme masculin, d'une tumeur de Wilms, d'une néphropathie parenchymateuse et d'un mosaicisme XX/XY. Arch Fr Pediatr 1967, 24:729-739
2. Drash A, Sherman F, Hartmann W, Blizzard RMA: A syndrome of pseudohermaphroditism, Wilms' tumor, hypertension, and degenerative renal disease. J Pediatr 1970, 76:585-593
3. Habib R, Loirat C, Gubler MC, Niaudet P, Bensman A, Levy M, Broyer M: The nephropathy associated with male pseudohermaphroditism and Wilms' tumor (Drash syndrome): a distinctive glomerular lesion, report of 10 cases. Clin Nephrol 1985, 24:269-278
4. Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, Striegel JE, Houghton DC, Junien C, Habib R, Fouser L, Fine RN, Silverman BL, Haber DA, Housman D: Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991, 67:437-447
5. Little M, Wells C: A clinical overview of WT1 gene mutations. Hum Mutat 1997, 9:209-225
6. Jeanpierre C, Béroud C, Niaudet P, Junien C: Software and database for the analysis of mutations in the human WT1 gene. Nucleic Acids Res 1998, 26:273-277
7. Jeanpierre C, Denamur E, Henry I, Cabanis MO, Luce S, Cécille A, Elion J, Peuchmaur M, Loirat C, Niaudet P, Gubler MC, Junien C: Identification of constitutional WT1 mutations in patients with isolated diffuse mesangial sclerosis (IDMS) and anlysis of genotype-phenotype correlations using a computerized mutation database. Am J Hum Genet 1998, 62:824-833
8. Habib R, Gubler MC, Antignac C, Gagnadoux MF: Diffuse mesangial sclerosis: a congenital glomerulopathy with nephrotic syndrome. Adv Nephrol 1993, 22:43-56
9. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Krai A, Yeger H, Lewis WH, Jones C, Housman DE: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990, 60:509-520
10. Gessler M, König A, Bruns GAP: The genomic organization and expression of the WT1 gene. Genomics 1992, 12:807-813
11. Wang ZY, Qiu QQ, Deuel TF: The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. J Biol Chem 1993, 268:9172-9175
12. Wang ZY, Qiu QQ, Huang J, Gurrieri M, Deuel TF: Products of alternative spliced transcripts of the Wilms' tumor suppressor gene, WT1, have altered DNA binding specificity and regulate transcription in different ways. Oncogene 1995, 10:415-422
13. Moffett P, Bruening W, Nakagama H, Bardeesy N, Housman DE, Pelletier J: Antagonism of WT1 activity by protein sell-association. Proc Natl Acad Sci USA 1995, 92:11105-11109
14. Caricasole A, Duarte A, Larsson SH, Hastie ND, Little M, Holmes G, Todorov I, Ward A: RNA binding by the Wilms tumor suppressor zinc finger proteins. Proc Natl Acad Sci USA 1996, 93:7562-7566
15. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE: Alternative splicing and genomic structure of the Wilms' tumor gene WT1. Proc Natl Acad Sci USA 1991, 88:9618-9622
16. Englert C, Vidal M, Maheswaran S, Ge YM, Ezzell RM, Isselbacher KJ, Haber DA: Truncated WT1 mutants alter the subnuclear localization of the wide-type protein. Proc Natl Acad Sci USA 1995, 92:11960-11964
17. Larsson SH, Charlieu JP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, van Heningen V, Hastie ND: Subnuclear localization of WT1 in splicing or transcription factor is regulated by alternative spicing. Cell 1995, 81:391-401
18. Saxén L, Sariola H: Early organogenesis of the kidney. Pediatr Nephrol 1987, 1:385-392
19. Kanwar YS, Carone FA, Kumar A, Wada J, Ota K, Wallner EI: Role of extracellular matrix, growth factors and proto-oncogenes in metanephric nevelopment. Kidney Int 1997, 52:589-606
20. Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C, Bard J, Buckler A, Pelletier J, Housman D, van Heyningen V, Hastie N: The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990, 346:194-197
21. Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE: Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol 1991, 11:1707-1712
22. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R: WT1 is required for early kidney development. Cell 1993, 74:679-691
23. Little MH, Williamson KA, Mannens M, Kelsey A, Gosden C, Hastie ND, van Heyningen V: Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. Hum Mol Genet 1993, 2:259-264
24. Little M, Holmes G, Bickmore W, Heyningen VV, Hastie N, Wainwright B: DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Hum Mol Genet 1995, 4:351-358
25. Dressler GR, Deutsch U, Chowdhury K, Nornes HO, Gruss P: Pax2, a new murine paired-box containing gene, and its expression in the developing excretory system. Development 1990, 109:787-795
26. Dressler GR, Douglass EC: Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms' tumor Proc Natl Acad Sci USA 1992, 89:1179-1183
27. Ryan G, Steele-Perkins V, Morris JF, Rauscher III FJ, Dressler GR: Repression of Pax-2 by WT1 during normal kidney development. Development 1995, 121:867-875
28. Dehbi M, Ghahremani M, Lechner M, Dressler G, Pelletier J: The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1). Oncogene 1996, 13:447-453
29. Dressler GR, Wilkinson JE, Rothenpieler UW, Patterson LT, Williams-Simons L, Westphal H: Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities. Nature 1993, 362:65-67
30. Torres M, Gomez-Pardo E, Dressier GR, Gruss P: Pax-2 controls multiple steps of urogenital development. Development 1995, 121: 4057-4065
31. Charles AK, Mall S, Watson J, Berry PJ: Expression of the Wilms' tumor gene WT1 in the developing human and in pediatric renal tumours: an immunohistochemical study. Mol Pathol 1997, 50:138-144
32. Phelps DA, Dressler GR: Identification of novel Pax-2 binding sites by chromatin precipitation. J Biol Chem 1996, 271:7978-7985
33. Winyard PJD, Risdon RA, Sams VR, Dressler GR, Woolf AS: The Pax2 transcription factor is expressed in cystic and hyperproliferative dysplestic epithelium in human kidney malformations. J Clin Invest 1996, 98:541-549
34. Rauscher III FJ: The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J 1993, 7:896-903
35. Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterpacht A, Zabel B: Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development 1993, 119:1329-1341
36. Grubb GR, Yun K, Williams BRG, Eccles MR, Reeve AE: Expression of WT1 proten in fetal kidneys and Wilms' tumors. Lab Invest 1994, 71:472-479
37. Ramani P, Cowell JK: The expression pattern of Wilms' tumor gene (WT1) product in normal tissues and paediatric renal tumors. J Pathol 1996, 179:162-168
38. Bruening W, Moffett P, Chia S, Heinrich G, Pelletier J: Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product. FEBS Lett 1996, 393:41-47
39. Reddy JC, Morris JC, Wang J, English MA, Haber DA, Shi Y, Licht JD: WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem 1995, 270:10878-10884
40. Eccles MR, Yun K, Reeve AE, Fidler AE: Comparative in situ hybridization analysis of Pax2, Pax8, and WT1 gene transcription in human fetal kidney, and Wilms' tumors. Am J Pathol 1995, 146:40-45
41. Eccles MR, Wallis LJ, Fidler AE, Spurr NK, Goodfellow PJ, Reeve AE: Expression of the Pax2 gene in human fetal kidney and Wilms tumor. Cell Growth Differ 1992, 3:279-289
42. Nagata M, Yamaguchi Y, Ito K: Loss of mitotic activity and the expression of vimentin in glomerular epithelial cells of developing human kidneys. Anat Embryol 1995, 192:385-397
43. Wang ZY, Madden SL, Deuel TF, Rauscher III FJ: The human platelet-derived growth factor A-chain (PDGF-A) gene is a target for repression by the WT1 Wilms tumor protein. J Biol Chem 1992, 267:21999-22002
44. Gashler AL, Bonthron DT, Madden SL, Rauscher III FJ, Collins T, Sukhatme VP: Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci USA 1992, 89:10984-10988
45. Drummond IA, Madden SL, Rowher-Nutter P, Bell GI, Sukhatme VP, Rauscher III FJ: Repression of the insulin-like growth factor-II gene by the Wilms tumor suppressor WT1. Science 1992, 257:674-678
46. Dey BR, Sukhatme VP, Roberts AB, Sporn MB, Rauscher III FJ, Kim SJ: Repression of the transforming growth factor-β 1 by the Wilmús' tumor suppressor WT1 gene product. Mol Endocrinol 1994, 8:595-602
47. Martinerie C, Chevalier G, Rauscher III FJ, Perbal B: Regulation of nov by WT1: a potential role for nov in nephrogenesis. Oncogene 1996, 12:1479-1492
48. Beale MC, Stayer DS, Kissane JM, Robson AM: Congenital glomerulosclerosis and nephrotic syndrome in 2 infants. Am J Dis Child 1979, 133:842-845
49. Uraoka YR, Murata R, Maki S: Infantile nephrotic syndrome: report of an infant with diffuse mesangial sclerosis. Acta Medica Kinkin Univ 1981, 6:7-18
50. Barakat AY, Khoury LA, Allam CK, Najjar SS: Diffuse mesangial sclerosis and ocular abnormalities in two siblings. Int J Pediatr Nephrol 1982, 3:33-35
51. Mendelsohn HB, Krauss M, Berant M, Lichtig C. Familial early onset nephrotic syndrome: diffuse mesangial sclerosis. Acta Paediatr Scand 1982, 71:753-758
52. Gaudelius J, Leverger J, Rault G, Nathanson M, Giorno JL, Boccon-Gibod L, Levy M, Broyer M: Association d'un syndrome néphrotique à début précoce et d'une microcéphalie: a propos de 4 observations dans 2 families. Arch Fr Pediatr 1984, 41:409-415
53. Urbach J, Drukker A, Rosenmann E: Diffuse mesangial sclerosis, light, immunofluorescent and electron microscopic findings. Int J Paediatr Nephrol 1985, 6:101-104
54. Von Eggert W, Eggert S, Ditscherlein G, Grossmann P, Devaux S: Die Mesangiumsklerose als Ursache des familiären Nephrotischen syndroms. Kinderärztl Praxis 1987, 55:295-302
55. Glastre C, Cochat P, Bouvier R, Colon S, Cottin X, Giffon D, Wright C, Dijoud F, David L: Familial infantile nephrotic syndrome with ocular abnormalities. Pediatr Nephrol 1990, 4:340-342
56. Garty BZ, Eisenstem B, Snadbank J, Kaffe S, Dagan R, Gadoth N: Microcephaly and congenital nephrotic syndrome owing to diffuse mesangial sclerosis: an autosomal recessive disease. J Med Genet 1994, 31:121-125
57. Ozen S, Tinaztepe K: Diffuse mesangial sclerosis: a unique type of congenital and infantile nephrotic syndrome. Nephron 1996, 72:288-291